Teachers Insurance & Annuity Association of America Makes New $46,000 Investment in Solventum Co. (NYSE:SOLV)

Teachers Insurance & Annuity Association of America purchased a new position in shares of Solventum Co. (NYSE:SOLV) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 662 shares of the company’s stock, valued at approximately $46,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Copeland Capital Management LLC bought a new stake in Solventum during the third quarter worth about $26,000. Mather Group LLC. bought a new stake in shares of Solventum in the 3rd quarter valued at about $27,000. EverSource Wealth Advisors LLC bought a new stake in shares of Solventum in the 1st quarter valued at about $30,000. Hollencrest Capital Management bought a new stake in shares of Solventum in the 2nd quarter valued at about $25,000. Finally, Deseret Mutual Benefit Administrators bought a new stake in shares of Solventum in the 2nd quarter valued at about $25,000.

Solventum Stock Performance

Shares of SOLV stock traded up $0.99 during midday trading on Thursday, reaching $72.48. 702,921 shares of the stock were exchanged, compared to its average volume of 1,695,591. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The company’s 50 day moving average is $70.51 and its two-hundred day moving average is $62.47. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group boosted their target price on Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research note on Monday, August 12th. Morgan Stanley boosted their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. BTIG Research began coverage on Solventum in a research report on Thursday, September 5th. They set a “neutral” rating for the company. Piper Sandler upped their price target on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. Finally, Stifel Nicolaus began coverage on Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Solventum has a consensus rating of “Hold” and a consensus target price of $68.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.